Literature DB >> 21852804

Neurosensory retinal detachment due to sunitinib treatment.

A Wegner, R Khoramnia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21852804      PMCID： PMC3213658          DOI： 10.1038/eye.2011.200

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

Review 1.  Systemic disorders associated with detachment of the neurosensory retina and retinal pigment epithelium.

Authors:  T J Wolfensberger; A Tufail
Journal:  Curr Opin Ophthalmol       Date:  2000-12       Impact factor: 3.761

Review 2.  Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.

Authors:  Brian I Rini
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

Review 3.  Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.

Authors:  Pascal Wolter; Patrick Schöffski
Journal:  Acta Oncol       Date:  2010       Impact factor: 4.089

Review 4.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

5.  Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.

Authors:  Karen B Schaal; Alexandra E Hoeh; Alexander Scheuerle; Florian Schuett; Stefan Dithmar
Journal:  Eur J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 2.597
  5 in total
  8 in total

Review 1.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

2.  Presumed bilateral diffuse uveal melanocytic proliferation - A case report and review of literature.

Authors:  Shweta Parakh; Shrey Maheshwari; Shrutanjoy Das; Vinod Kumar; Rupesh Agrawal; Vishali Gupta; Prithvi Mruthyunjaya; Saurabh Luthra
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-13

Review 3.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 4.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

5.  Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: A case report.

Authors:  Nolan J Adams; Felipe De Alba
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-07

6.  A case of retinal tear associated with use of sorafenib.

Authors:  Kelly M Gaertner; Stephen H Caldwell; Osama E Rahma
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

7.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500

Review 8.  [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Juhong Shi; Meifen Zhang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.